Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Sanofi's lunsekimig met primary  and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status   The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig's potential as a respiratory treatment The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis In all studies, lunsekimig was well tolerated Paris, April 7, 2026. Phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo.